Get the Stockscreener App
8.98
6.85%
-0.66
Kalaris Therapeutics Inc stock is traded at $8.98, with a volume of 52,974.
It is down -6.85% in the last 24 hours and up +1.58% over the past month.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
See More
Previous Close:
$9.64
Open:
$9.63
24h Volume:
52,974
Relative Volume:
0.42
Market Cap:
$167.95M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+7.54%
1M Performance:
+1.58%
6M Performance:
+260.64%
1Y Performance:
+0.00%
1-Day Range:
$8.80
$9.90
1-Week Range:
$8.29
$10.28
52-Week Range:
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Name
Kalaris Therapeutics Inc
Sector
Industry
Phone
650-249-2727
Address
400 CONNELL DRIVE, BERKELEY HEIGHTS
Compare KLRS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
8.98 | 180.29M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-25 | Initiated | Chardan Capital Markets | Buy |
| Nov-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Jul-23-25 | Resumed | Piper Sandler | Neutral |
| May-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-08-25 | Initiated | William Blair | Outperform |
View All
Kalaris Therapeutics Inc Stock (KLRS) Latest News
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Why Kalaris Therapeutics Inc. stock is trending among retail tradersQuarterly Investment Review & High Return Trade Opportunity Guides - mfd.ru
Kalaris Therapeutics Emerges with Focused Retinal Disease Strategy - AD HOC NEWS
Institution Moves: Whats the profit margin of Kalaris Therapeutics IncTrade Exit Report & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Increases By 60.8% - MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Smart Money: Should I add Kalaris Therapeutics Inc stock to my portfolioJuly 2025 Big Picture & Real-Time Buy Signal Notifications - baoquankhu1.vn
Kalaris to present phase 1 data of novel eye therapy at Macula Society - Investing.com Australia
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting - Investing News Network
Kalaris Therapeutics (NASDAQ:KLRS) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Kalaris Therapeutics raises $50M privately - MSN
What’s the MACD signal for Kalaris Therapeutics Inc.Double Top/Bottom Patterns & High Return Capital Strategies - bollywoodhelpline.com
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Buyback Watch: Will Kalaris Therapeutics Inc outperform small cap indexesJuly 2025 Recap & Fast Moving Stock Trade Plans - baoquankhu1.vn
Block Trades: Can Kalaris Therapeutics Inc weather a recessionWeekly Earnings Recap & Real-Time Price Movement Reports - baoquankhu1.vn
Swing Trade: Is Kalaris Therapeutics Inc. affected by consumer sentimentInsider Buying & AI Forecasted Stock Moves - baoquankhu1.vn
Support Test: What is Kalaris Therapeutics Incs 5 year growth outlookRecession Risk & AI Powered Market Entry Ideas - baoquankhu1.vn
How Kalaris Therapeutics Inc. stock responds to policy changesMarket Sentiment Report & Technical Pattern Based Buy Signals - Улправда
Why retail investors pile into Kalaris Therapeutics Inc. stockJuly 2025 Trade Ideas & Long-Term Investment Growth Plans - Улправда
Is Kalaris Therapeutics Inc. stock a defensive play in 2025Treasury Yields & Reliable Volume Spike Trade Alerts - Улправда
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Expands By 26.1% - MarketBeat
Analysts’ Weekly Ratings Updates for Kalaris Therapeutics (KLRS) - Defense World
Chardan Capital Initiates Coverage on Kalaris Therapeutics (NASDAQ:KLRS) - Defense World
Kalaris Therapeutics announces initial data from TH103 trial - MSN
Chardan Capital Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Strong-Buy - MarketBeat
Chardan Capital Initiates Coverage of Kalaris Therapeutics (KLRS) with Buy Recommendation - Nasdaq
Chardan Initiates Kalaris Therapeutics at Buy With $19 Price Target - marketscreener.com
Chardan Capital Markets initiates coverage on Kalaris stock with Buy rating - Investing.com Nigeria
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Why Kalaris Therapeutics Inc. stock is rated strong buyJuly 2025 Chart Watch & Real-Time Volume Triggers - Улправда
KLRS Kalaris Therapeutics Inc +8.76%eToro - eToro
Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Why Kalaris Therapeutics Inc. stock is popular among millennialsJuly 2025 WrapUp & AI Powered Market Entry Strategies - Улправда
Will Kalaris Therapeutics Inc. stock deliver long term returnsJuly 2025 Momentum & Comprehensive Market Scan Reports - Улправда
Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts (KLRS) - Seeking Alpha
Targets Report: Why Kalaris Therapeutics Inc. stock is popular among millennialsTrade Performance Summary & Smart Swing Trading Alerts - Улправда
Latham & Watkins Advises on Kalaris Therapeutics’ US$50 Million Private Placement - Legal Desire Media and Insights
Fundamentals Check: Will Kalaris Therapeutics Inc. stock outperform growth indexesJuly 2025 Reactions & Reliable Momentum Entry Alerts - Улправда
Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth (KLRS) - Seeking Alpha
Kalaris stock price target raised to $26 at Citizens on TH103 data - Investing.com Canada
Kalaris Therapeutics Announces Oversubscribed $50 Million Financing - TipRanks
Kalaris Therapeutics Signs Multiple Material Agreements - TradingView — Track All Markets
Kalaris Therapeutics (NASDAQ: KLRS) lines up $50M private placement - Stock Titan
Kalaris Therapeutics Inc Stock (KLRS) Financials Data
There is no financial data for Kalaris Therapeutics Inc (KLRS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):